Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Meyer, S.; Nederend, M.; Jansen, J.H.M.; Reiding, K.R.; Jacobino, S.R.; Meeldijk, J.; ... ; Leusen, J.H.W. (2016)

Article / Letter to editor

• albumin-binding domain (ABD)
• antibody therapy
• Fc a receptor (FcaRI)
• glycosylation
• half-life extension
• IgA
• neonatal Fc receptor (FcRn)
• serum exposure

• All authors: Meyer, S.; Nederend, M.; Jansen, J.H.M.; Reiding, K.R.; Jacobino, S.R.; Meeldijk, J.; Bovenschen, N.; Wuhrer, M.; Valerius, T.; Ubink, R.; Boross, P.; Rouwendal, G.; Leusen, J.H.W.
• Date: 2016-01-02
• Journal: mAbs
• Volume: 8
• Issue: 1
• Pages: 87 - 98
• DOI: doi:10.1080/19420862.2015.1106658